Long-acting polypeptides and methods of producing and administering same
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
1. A method of reducing the dosing frequency of a growth hormone in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified growth hormone with one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said growth hormone and two chorionic gonadotrophin CTPs attached to the carboxy terminus of said growth hormone, wherein said modified growth hormone optionally comprises a signal peptide attached to the amino terminus of said one CTP, and wherein the dosing frequency of said modified growth hormone is thereby reduced as compared to the dosing frequency of a corresponding unmodified growth hormone in a subject.
2. The method of claim 1 , wherein the sequence of at least one CTP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18.
3. The method of claim 1 , wherein said at least one CTP is glycosylated.
4. The method of claim 1 , wherein said at least one CTP is truncated.
5. The method of claim 1 , wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19.
6. The method of claim 1 , wherein at least one CTP is optionally attached to said growth hormone via a linker.
7. The method of claim 6 , wherein the linker is a peptide bond.
8. The method of claim 1 , wherein said modified growth hormone is administered once weekly, once every two weeks, or once every three weeks.
9. The method of claim 1 , wherein said subject is a human subject.
10. The method of claim 1 , wherein said growth hormone is human growth hormone (hGH).
11. The method of claim 1 , wherein said modified growth hormone is administered via the subcutaneous route.
12. The method of claim 1 , wherein said modified growth hormone is administered via the intravenous route.
13. The method of claim 1 , wherein said modified growth hormone is administered at a dosage range of 0.01-50 mg/week.
14. The method of claim 1 , wherein said modified growth hormone is administered at a dosage range of 0.1-20 mg/week.
15. The method of claim 1 , wherein said modified growth hormone is administered at a dosage range of 0.1-10 mg/week.
16. The method of claim 1 , wherein said modified growth hormone is administered at a dosage range of 0.5-50 mg/week.
17. A method of improving the area under the curve (AUC) of a growth hormone in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified growth hormone with one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said growth hormone and two chorionic gonadotrophin CTPs attached to the carboxy terminus of said growth hormone, wherein said modified growth hormone optionally comprises a signal peptide attached to the amino terminus of said one CTP, and wherein the AUC of said modified growth hormone is thereby improved as compared to the AUC of a corresponding unmodified growth hormone in a subject.
18. The method of claim 17 , wherein the sequence of at least one CTP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18.
19. The method of claim 17 , wherein said at least one CTP is glycosylated.
20. The method of claim 17 , wherein said at least one CTP is truncated.
21. The method of claim 17 , wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19.
22. The method of claim 17 , wherein at least one CTP is optionally attached to said growth hormone via a linker.
23. The method of claim 22 , wherein the linker is a peptide bond.
24. The method of claim 17 , wherein said modified growth hormone is administered once weekly, once every two weeks, or once every three weeks.
25. The method of claim 17 , wherein said subject is a human subject.
26. The method of claim 17 , wherein said growth hormone is human growth hormone (hGH).
27. The method of claim 17 , wherein said modified growth hormone is administered via the subcutaneous route.
28. The method of claim 17 , wherein said modified growth hormone is administered via the intravenous route.
29. The method of claim 17 , wherein said modified growth hormone is administered at a dosage range of 0.01-50 mg/week.
30. The method of claim 17 , wherein said modified growth hormone is administered at a dosage range of 0.1-20 mg/week.
31. The method of claim 17 , wherein said modified growth hormone is administered at a dosage range of 0.1-10 mg/week.
32. The method of claim 17 , wherein said modified growth hormone is administered at a dosage range of 0.5-50 mg/week.